Document Detail

Renoprotection, renin inhibition, and blood pressure control: the impact of aliskiren on integrated blood pressure control.
MedLine Citation:
PMID:  21949629     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Hypertension (HTN) is an important factor in progressive loss of renal function. The kidney can be both a contributor to and a target of HTN. The functional integrity of the kidney is vital for the maintenance of cardiovascular homeostasis. Chronic activation of the renin system causes HTN and, ultimately, end-organ damage. Direct renin inhibitors (DRIs) inhibit plasma renin activity (PRA), thereby preventing the conversion of angiotensinogen to angiotensin I; consequently, the levels of both Ang I and Ang II are reduced. There is no compensatory increase in PRA activity with DRIs as seen with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). There are reasons to speculate that renin inhibition might prove to be a superior strategy for blocking the renin-angiotensin-aldosterone system compared with ACEIs or ARBs. Evidence for the efficacy of aliskiren (a DRI) is considered to be relatively strong, based on published, short-term, double-blind, randomized, controlled trials showing that aliskiren is as effective as other antihypertensive agents in reducing blood pressure (BP), with no rebound effects on BP after treatment withdrawal. When combined with diuretics, fully additive BP reduction is seen. When given with an ACEI or ARB, aliskiren produces significant additional BP reduction indicative of complimentary pharmacology and more complete renin-angiotensin system blockade.
Haroon-Ur Rashid
Related Documents :
6580879 - Errors in the measurement of blood pressure.
8186589 - Lumbar paraspinal compartment pressure in back muscle exercise.
21722579 - Biomechanics of the sensor-tissue interface-effects of motion, pressure, and design on ...
9689699 - Effects of exaggerated lithotomy position on ventilation and hemodynamics during radica...
1416389 - Tachykinins increase respiratory clearance of 99mtc-dtpa. mechanisms of action.
24085809 - The jugular venous pressure revisited.
7263399 - Lung fluid and protein exchange in the acute sheep preparation.
24823179 - Peripheral nerve compression: etiology, critical pressure threshold, and clinical asses...
10351639 - North american approach to smoke management.
Publication Detail:
Type:  Journal Article     Date:  2010-10-05
Journal Detail:
Title:  Integrated blood pressure control     Volume:  3     ISSN:  1178-7104     ISO Abbreviation:  Integr Blood Press Control     Publication Date:  2010  
Date Detail:
Created Date:  2011-09-28     Completed Date:  2011-11-10     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  101562709     Medline TA:  Integr Blood Press Control     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  133-44     Citation Subset:  -    
Department of Cardiology, Baylor College of Medicine, Texas Heart Institute, Houston, TX, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Is tetrahydrobiopterin a therapeutic option in diabetic hypertensive patients?
Next Document:  Optimal management of hypertension in elderly patients.